Use of surrogate markers for drugs of military importance

Military Medicine

Volumn 163, Issue 11, 1998, Pages 743-746

  Marino, Mark T ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL WARFARE AGENT; CYANIDE; METHEMOGLOBIN;

ARTICLE; CHEMICAL WARFARE; DISEASE MARKER; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; MEDICAL ETHICS; PROPHYLAXIS;

EID: 0031793465     PISSN: 00264075     EISSN: None     Source Type: Journal    
DOI: 10.1093/milmed/163.11.743     Document Type: Article

References (19)

1. Flanagin A, Lederberg J: The threat of biological weapons: prophylaxis and mitigation. Call for papers. JAMA 1996; 276: 419-20.
2. Stephenson J: Confronting a biological armageddon: experts tackle prospect of bioterrorism. JAMA 1996; 276: 349-51.
3. Smith RJ: Japanese cult had a network of front companies, investigators say. Washington Post November 1, 1995, p 8.
4. Daplam DE, Marshall A: The Cult of the End of the World. New York, Crown Publishing Group, 1996.
5. Mars TC, Maynard RL, Sidell FR: A history of human studies with nerve agents by the UK and the USA. In Chemical Warfare Agents: Toxicology and Treatment, pp 115-37. New York, Wiley, 1983.
6. Senanayake N, Karalliedde L: Neurotoxic effects of organophosphorus insecticides: an intermediate syndrome. N Engl J Med 1987; 316: 761-3.
7. Temple RJ: A regulatory authority's opinion about surrogate endpoints. In Clinical Measurement in Drug Evaluation. New York, Wiley, 1995.
8. Colburn WA: Selecting and validating biological markers for drug development. J Clin Pharmacol 1997; 37: 355-62.
9. Fleming TR, DeMets DL: Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996; 125: 605-13.
10. Amin R: Plight of the Kurdish people. Br Med J 1994; 309: 875-6.
11. Ballyantyne B: Toxicology of cyanides. In Clinical and Experimental Toxicology of Cyanides, pp 41-127. UK, Wright Bristol, 1987.
12. Klaassen CD: Nonmetallic environmental toxicants: air pollutants, solvents and vapors, and pesticides. In The Pharmacological Basis of Therapeutics, pp 1673-96. New York, Pergamon Press, 1996.
13. Albaum HG, Tepperman J, Bodansky O: A spectrophotometric study of the competition of methemoglobin and cytochrome oxidase for cyanide in vitro. J Biol Chem 1946; 163: 641-7.
14. Kirk MA, Gerace R, Kulig KW: Cyanide and methemoglobin kinetics in smoke inhalation victims treated with the cyanide antidote kit. Ann Emerg Med 1993; 22: 1413-8.
15. Marrs TC: The choice of cyanide antidotes. In Clinical and Experimental Toxicology of Cyanides, pp 383-402. UK, Wright Bristol, 1987.
16. Smith TM, Harber E, Yeatman L, Butler VP Jr: Reversal of advanced digoxin intoxication with Fab fragments of digoxin-speciflc antibodies. N Engl J Med 1976; 294: 797-800.
17. Menton RG, Reid FM, Niemuth NA, Audet KK, Marino M, Brewer TG, Korte DW: An evaluation of three methemoglobin forming compounds as pretreatment for cyanide intoxication. Medical Defense Bioscience Review 1996; 1286-94.
18. Radetsky P: The Gulf War within. Discover 1997; 18: 68-75.
19. Hyams KC, Wignall FS, Roswell R: War syndromes and their evaluation: from the U.S. Civil War to the Persian Gulf War. Ann Intern Med 1996; 125: 398-405.